Dr. Neil Kumar Agarwal, MD

Dr. Agarwal practices at University of Maryland Medical Center Midtown Campus in Baltimore, Maryland, part of University of Maryland Medical System.

Dr. Agarwal's NPI, 1699157230, was assigned on June 19, 2015. Dr. Agarwal holds Maryland license D89537.

Dr. Agarwal's primary practice is University of Maryland Medical Center Midtown Campus, at 827 Linden Avenue, Baltimore, MD 21201 in Baltimore City. The practice phone is (410) 225-8996.

Dr. Agarwal's primary practice is University of Maryland Medical Center Midtown Campus in Baltimore, Maryland, part of University of Maryland Medical System. Dr. Agarwal is also affiliated with University of Maryland Medical Center. The medical group on file is University of Maryland Medical Center Gastroenterology and Hepatology.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Agarwal practices, 2 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Agarwal's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Agarwal is licensed in Maryland.

CMS data shows 824 Medicare services from Dr. Agarwal across 9 procedure codes in 2024, for 279 Medicare patients. Medicare paid $67,151 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 279 Medicare patients who saw Dr. Agarwal in 2024. The largest group is 65 to 74, with 99 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 42% are also on Medicaid. Their average risk score is 4.34, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Agarwal's median patient age at 68, with 51% women.

In 2024, Dr. Agarwal wrote 118 Medicare Part D claims for 33 patients. 76% of them were for generic drugs. CMS names the drug for 36 of them, across 2 drugs with 11 or more claims each, at $13,767 in total drug cost. In 2023, CMS named 27 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Agarwal for performance year 2024, reported as part of a group. Dr. Agarwal accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 1 paper to Dr. Agarwal in 2025.

CMS Open Payments shows 39 general payments to Dr. Agarwal from 15 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 89% of the total. Relypsa, Inc. paid the most, $275.